[go: up one dir, main page]

MXPA03011793A - Interferon formulations. - Google Patents

Interferon formulations.

Info

Publication number
MXPA03011793A
MXPA03011793A MXPA03011793A MXPA03011793A MXPA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A
Authority
MX
Mexico
Prior art keywords
interferon
compositions
interferon formulations
relates
formulations
Prior art date
Application number
MXPA03011793A
Other languages
Spanish (es)
Inventor
Drustrup Jorn
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of MXPA03011793A publication Critical patent/MXPA03011793A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to interferon compositions, such as pharmaceutical interferon compositions and methods of their preparation. In particular it relates to stabilized compositions comprising an interferon polypeptide and a sulfoalkyl ether cyclodextrin derivative.
MXPA03011793A 2001-06-29 2002-06-28 Interferon formulations. MXPA03011793A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200101040 2001-06-29
DKPA200101277 2001-08-30
DKPA200200257 2002-02-19
PCT/DK2002/000444 WO2003002152A2 (en) 2001-06-29 2002-06-28 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins

Publications (1)

Publication Number Publication Date
MXPA03011793A true MXPA03011793A (en) 2004-04-02

Family

ID=27222516

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011793A MXPA03011793A (en) 2001-06-29 2002-06-28 Interferon formulations.

Country Status (7)

Country Link
EP (1) EP1414498A2 (en)
JP (1) JP2004522803A (en)
CN (1) CN1522159A (en)
CA (1) CA2452364A1 (en)
MX (1) MXPA03011793A (en)
RU (1) RU2004102500A (en)
WO (1) WO2003002152A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US9125880B2 (en) 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
AU2004298781B2 (en) * 2003-12-11 2010-04-01 Ares Trading S.A. Stabilized interferon liquid formulations
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
WO2005120551A1 (en) * 2004-06-07 2005-12-22 Nastech Pharmaceutical Company Inc. Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
JP4944112B2 (en) * 2005-08-26 2012-05-30 アレス トレーディング ソシエテ アノニム Process for the preparation of glycosylated interferon beta
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
CA2644127A1 (en) * 2006-03-08 2007-09-13 Biomethodes Human interferon-gamma (infgamma) variants
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
BRPI0821029A2 (en) 2007-12-20 2015-06-16 Merck Serono Sa Peg-interferon-beta formulations
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
PE20120169A1 (en) * 2008-11-17 2012-02-29 Genentech Inc METHOD AND FORMULATION TO REDUCE THE AGGREGATION OF A MACROMOLECLE UNDER PHYSIOLOGICAL CONDITIONS
DK3100728T3 (en) 2009-05-13 2020-02-17 Cydex Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS COMPREHENSIVE PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS FOR PREPARING AND USING SAME
RU2482871C2 (en) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Composition for treating viral diseases in animals
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450019A1 (en) 2011-10-21 2014-01-10 Abbvie Inc Methods for treating HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US10012064B2 (en) 2015-04-09 2018-07-03 Highlands Natural Resources, Plc Gas diverter for well and reservoir stimulation
US10344204B2 (en) 2015-04-09 2019-07-09 Diversion Technologies, LLC Gas diverter for well and reservoir stimulation
KR20250052501A (en) 2015-12-30 2025-04-18 제넨테크, 인크. Formulations with reduced degradation of polysorbate
US10982520B2 (en) 2016-04-27 2021-04-20 Highland Natural Resources, PLC Gas diverter for well and reservoir stimulation
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
JP7105200B2 (en) * 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ Targeted mutant interferon-beta and its uses
MX2021001165A (en) * 2018-07-30 2021-07-15 Univ Leland Stanford Junior Interferon-gamma biased agonists.
CN111358938B (en) * 2020-03-30 2023-08-11 温州肯恩大学(Wenzhou-KeanUniversity) Combination medicine of human interferon-ε and interferon-γ and its application
CN113797317B (en) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 Composition, and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
PT986403E (en) * 1997-06-13 2004-04-30 Cydex Inc COMPOSITION WITH A LONG-TERM STORAGE LIFE COMPREHENING CYCLODEXTRIN AND DRUGS OR PRODUKES THAT DECOMPOSE IN INSOLULE COMPOUNDS IN WATER

Also Published As

Publication number Publication date
WO2003002152A3 (en) 2003-05-01
RU2004102500A (en) 2005-04-10
WO2003002152A2 (en) 2003-01-09
EP1414498A2 (en) 2004-05-06
CA2452364A1 (en) 2003-01-09
CN1522159A (en) 2004-08-18
JP2004522803A (en) 2004-07-29

Similar Documents

Publication Publication Date Title
MXPA03011793A (en) Interferon formulations.
YU27403A (en) Method for producing powdery formulations
WO2001058412A3 (en) Extracts from residues left in the production of wine
AU2002305099A1 (en) Fatty alcohol drug conjugates
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
WO2004043363A3 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
MY142354A (en) Acidic insulin preparations having improved stability
CY2016024I2 (en) SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR ITS PREPARATION, USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
HUS1800013I1 (en) Oral formulations of cladribine
MXPA04005517A (en) Pharmaceutical compositions in the form of gel or solution based on dihydrotestosterone, preparation method and uses thereof.
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
WO2001005355A3 (en) Formulations for il-11
AU3281902A (en) Methods for the production of multimeric proteins, and related compositions
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2003086272A3 (en) Ultrapure transferrin for pharmaceutical compositions
WO2002096936A3 (en) Daptomycin and related analogs in crystalline form, their preparation and use
IL174479A (en) Hemiasterlin derivatives, pharmaceutical compositions comprising the same and uses thereof
DE50213839D1 (en) THIN-LIQUID, SPRAYING W / O EMULSIONS
MXPA03011128A (en) Flavour and fragrance compositions.
PL1677818T3 (en) Stable aqueous g-csf-containing compositions
WO2004073686A3 (en) Menthol solutions of drugs
MY138219A (en) Biologically active peptides
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
WO2006023465A8 (en) Polyethylene glycol-peptide copper complexes and compositions and methods related thereto
WO2001037780A8 (en) Urotensin-ii analogs